{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:00:24Z","timestamp":1793829624023,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100018780","name":"Junta de Andaluc\u00eda Servicio Andaluz de Salud","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.arbres.2025.02.004","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:56:30Z","timestamp":1740167790000},"page":"594-602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["All-Cause and Cardiovascular Mortality With Single Inhaler Triple Therapy Versus Double Therapies for COPD: A Systematic Review and Metanalysis"],"prefix":"10.1016","volume":"61","author":[{"given":"Ayoub","family":"Hammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Hoyas-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Romero-Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"\u00c1lvarez-Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Men\u00e9ndez-Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damaris","family":"Romeral-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jim\u00e9nez-Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Almansa-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Casares-Martin-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"S\u00e1nchez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Jose","family":"Romero-Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardino","family":"Alc\u00e1zar-Navarrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2025.02.004_bib0165","unstructured":"GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med; 2020; 8: 585\u201396. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32526187 [cited 21.6.20]."},{"key":"10.1016\/j.arbres.2025.02.004_bib0170","unstructured":"World Health Organisation. The top 10 causes of death [Internet]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death [cited 18.3.23]."},{"key":"10.1016\/j.arbres.2025.02.004_bib0275","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-2600(15)00241-6","article-title":"Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis","volume":"3","author":"Chen","year":"2015","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.arbres.2025.02.004_bib0180","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S2213-2600(24)00038-9","article-title":"MACE in COPD: addressing cardiopulmonary risk","volume":"12","author":"Hurst","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2025.02.004_bib0280","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/thx.2009.128082","article-title":"Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care","volume":"65","author":"Feary","year":"2010","journal-title":"Thorax."},{"key":"10.1016\/j.arbres.2025.02.004_bib0190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.rmed.2005.03.035","article-title":"Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study","volume":"100","author":"Mannino","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2025.02.004_bib0285","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/s41591-024-02905-y","article-title":"Development and validation of a new algorithm for improved cardiovascular risk prediction","volume":"30","author":"Hippisley-Cox","year":"2024","journal-title":"Nat Med."},{"key":"10.1016\/j.arbres.2025.02.004_bib0290","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.arbres.2023.02.009","article-title":"Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary","volume":"59","author":"Agust\u00ed","year":"2023","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.arbres.2025.02.004_bib0295","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","article-title":"FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease","volume":"196","author":"Lipson","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.arbres.2025.02.004_bib0300","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2025.02.004_bib0305","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2025.02.004_bib0310","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.arbres.2025.02.004_bib0315","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.arbres.2025.02.004_bib0320","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","article-title":"Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.arbres.2025.02.004_bib0325","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","article-title":"Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled tr","volume":"6","author":"Ferguson","year":"2018","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.arbres.2025.02.004_bib0330","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in All-Cause Mortality with Fluticasone Furoate\/Umeclidinium\/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease","volume":"201","author":"Lipson","year":"2020","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.arbres.2025.02.004_bib0335","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced All-Cause Mortality in the ETHOS Trial of Budesonide\/Glycopyrrolate\/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.arbres.2025.02.004_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15412555.2021.1977789","article-title":"Triple inhaler versus dual bronchodilator therapy in COPD: real-world effectiveness on mortality","volume":"19","author":"Suissa","year":"2022","journal-title":"COPD"},{"key":"10.1016\/j.arbres.2025.02.004_bib0255","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00615-2022","article-title":"Triple therapy in COPD: understanding the data","volume":"9.","author":"Suissa","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.arbres.2025.02.004_bib0340","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"10.1016\/j.arbres.2025.02.004_bib0345","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"10.1016\/j.arbres.2025.02.004_bib0270","article-title":"Single-inhaler triple vs long-acting beta2-agonist-inhaled corticosteroid therapy for COPD: comparative safety in real-world clinical practice","author":"Suissa","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2025.02.004_bib0350","doi-asserted-by":"crossref","first-page":"00950","DOI":"10.1183\/23120541.00950-2020","article-title":"INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice","volume":"7","author":"Halpin","year":"2021","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.arbres.2025.02.004_bib0355","doi-asserted-by":"crossref","first-page":"106807","DOI":"10.1016\/j.rmed.2022.106807","article-title":"Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study","volume":"197","author":"Mannino","year":"2022","journal-title":"Respir Med."},{"key":"10.1016\/j.arbres.2025.02.004_bib0360","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.chest.2022.06.033","article-title":"Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain","volume":"162","author":"Alc\u00e1zar-Navarrete","year":"2022","journal-title":"Chest."},{"key":"10.1016\/j.arbres.2025.02.004_bib0365","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.chest.2022.07.015","article-title":"Association of Inhaled Corticosteroids With All-Cause Mortality Risk in Patients With COPD: A Meta-analysis of 60 Randomized Controlled Trials","volume":"163","author":"Chen","year":"2023","journal-title":"Chest."},{"key":"10.1016\/j.arbres.2025.02.004_bib0370","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12931-019-1126-7","article-title":"Bone and ocular safety of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study","volume":"20","author":"Kerwin","year":"2019","journal-title":"Respir Res."},{"key":"10.1016\/j.arbres.2025.02.004_bib0375","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.2147\/COPD.S220861","article-title":"Long-Term Safety and Efficacy of Budesonide\/Glycopyrrolate\/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD","volume":"14","author":"Ichinose","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.arbres.2025.02.004_bib0380","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12931-020-01589-5","article-title":"The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone\/formoterol\/glycopyrronium on gas trapping in COPD","volume":"21","author":"Dean","year":"2020","journal-title":"Respir Res."},{"key":"10.1016\/j.arbres.2025.02.004_bib0385","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12931-021-01683-2","article-title":"Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial","volume":"22","author":"Zheng","year":"2021","journal-title":"Respir Res."},{"key":"10.1016\/j.arbres.2025.02.004_bib0390","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12931-021-01772-2","article-title":"Functional respiratory imaging assessment of budesonide\/glycopyrrolate\/formoterol fumarate and glycopyrrolate\/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids","volume":"22","author":"van den Berge","year":"2021","journal-title":"Respir Res."},{"key":"10.1016\/j.arbres.2025.02.004_bib0395","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/COPD.S291030","article-title":"Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate\/Formoterol Fumarate\/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial","volume":"16","author":"Beeh","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis."}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289625000626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289625000626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T22:14:44Z","timestamp":1759875284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289625000626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0300289625000626"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2025.02.004","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"All-Cause and Cardiovascular Mortality With Single Inhaler Triple Therapy Versus Double Therapies for COPD: A Systematic Review and Metanalysis","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2025.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}